Augmentation of Ouabain-Induced Increase in Heart Muscle Contractility by Akt Inhibitor MK-2206.
Animals
Cardiotonic Agents
/ pharmacology
Cells, Cultured
Disease Models, Animal
Drug Synergism
Drug Therapy, Combination
Heterocyclic Compounds, 3-Ring
/ pharmacology
Isolated Heart Preparation
Male
Myocardial Contraction
/ drug effects
Myocardial Infarction
/ drug therapy
Myocytes, Cardiac
/ drug effects
Ouabain
/ pharmacology
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-akt
/ antagonists & inhibitors
Rats, Wistar
Signal Transduction
Ventricular Function, Left
/ drug effects
Akt inhibitor
cardiac pharmacology
cardiac steroids
experimental cardiology
Journal
Journal of cardiovascular pharmacology and therapeutics
ISSN: 1940-4034
Titre abrégé: J Cardiovasc Pharmacol Ther
Pays: United States
ID NLM: 9602617
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
24
7
2018
medline:
1
1
2020
entrez:
24
7
2018
Statut:
ppublish
Résumé
Cardiac steroids (CSs), such as ouabain and digoxin, increase the force of contraction of heart muscle and are used for the treatment of congestive heart failure (CHF). However, their small therapeutic window limits their use. It is well established that Na
Identifiants
pubmed: 30033751
doi: 10.1177/1074248418788301
doi:
Substances chimiques
Cardiotonic Agents
0
Heterocyclic Compounds, 3-Ring
0
MK 2206
0
Protein Kinase Inhibitors
0
Ouabain
5ACL011P69
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM